NCT04034069

Brief Summary

The aim of this study is to investigate the effects of intermittent theta burst stimulation primed with continous theta burst stimulation (cTBS), on top of a standard robot-assisted training (RAT) on improving the upper limb motor functions of stroke survivors and to explore potential sensorimotor neuroplasticity with electroencephalography (EEG).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P50-P75 for not_applicable stroke

Timeline
Completed

Started Sep 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 23, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 26, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

September 9, 2019

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2021

Completed
Last Updated

August 30, 2021

Status Verified

August 1, 2021

Enrollment Period

1.7 years

First QC Date

July 23, 2019

Last Update Submit

August 24, 2021

Conditions

Keywords

stroketheta burst stimulationupper limbmetaplasticitypriming

Outcome Measures

Primary Outcomes (8)

  • Fugl-Meyer Assessment-Upper Extremity scores (FMA-UE)

    FMA-UE is a standard upper limb motor impairment assessment for stroke survivors. FMA-UE assesses voluntary movement, reflex activity, grasp and coordination.

    Baseline

  • Fugl-Meyer Assessment-Upper Extremity scores (FMA-UE)

    FMA-UE is a standard upper limb motor impairment assessment for stroke survivors. FMA-UE assesses voluntary movement, reflex activity, grasp and coordination.

    1 week

  • Fugl-Meyer Assessment-Upper Extremity scores (FMA-UE)

    FMA-UE is a standard upper limb motor impairment assessment for stroke survivors. FMA-UE assesses voluntary movement, reflex activity, grasp and coordination.

    2 weeks

  • Fugl-Meyer Assessment-Upper Extremity scores (FMA-UE)

    FMA-UE is a standard upper limb motor impairment assessment for stroke survivors. FMA-UE assesses voluntary movement, reflex activity, grasp and coordination.

    2 weeks after the completion of training

  • Action Research Arm Test (ARAT)

    ARAT is a standard upper limb functional performance assessment for stroke survivors. ARAT assesses a patient's ability to handle objects differing in size, weight and shape. ARAT consists of 19 items grouped into four subscales: grasp, grip, pinch, and gross movement.

    Baseline

  • Action Research Arm Test (ARAT)

    ARAT is a standard upper limb functional performance assessment for stroke survivors. ARAT assesses a patient's ability to handle objects differing in size, weight and shape. ARAT consists of 19 items grouped into four subscales: grasp, grip, pinch, and gross movement.

    1 week

  • Action Research Arm Test (ARAT)

    ARAT is a standard upper limb functional performance assessment for stroke survivors. ARAT assesses a patient's ability to handle objects differing in size, weight and shape. ARAT consists of 19 items grouped into four subscales: grasp, grip, pinch, and gross movement.

    2 week

  • Action Research Arm Test (ARAT)

    ARAT is a standard upper limb functional performance assessment for stroke survivors. ARAT assesses a patient's ability to handle objects differing in size, weight and shape. ARAT consists of 19 items grouped into four subscales: grasp, grip, pinch, and gross movement.

    2 weeks after the completion of training

Secondary Outcomes (4)

  • Sensorimotor event-related desynchronization

    Baseline

  • Sensorimotor event-related desynchronization

    2 weeks

  • Mean velocity

    Baseline

  • Mean velocity

    2 weeks

Study Arms (3)

cTBS + iTBS, in addition to robot-assisted training

EXPERIMENTAL

Participants will receive 10-session intervention of priming iTBS protocol (cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.

Device: Theta burst stimulation (TBS)Behavioral: Robot-assisted training

Sham cTBS + iTBS, in addition to robot-assisted training

ACTIVE COMPARATOR

Participants will receive 10-session intervention of non-primed, standard iTBS (sham cTBS followed by iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.

Device: Theta burst stimulation (TBS)Behavioral: Robot-assisted training

Sham cTBS + sham iTBS, in addition to robot-assisted training

SHAM COMPARATOR

Participants will receive 10-session intervention of sham stimulation (sham cTBS followed by sham iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.

Device: Theta burst stimulation (TBS)Behavioral: Robot-assisted training

Interventions

Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.

Also known as: Repetitive transcranial magnetic stimulation (rTMS)
Sham cTBS + iTBS, in addition to robot-assisted trainingSham cTBS + sham iTBS, in addition to robot-assisted trainingcTBS + iTBS, in addition to robot-assisted training

Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.

Sham cTBS + iTBS, in addition to robot-assisted trainingSham cTBS + sham iTBS, in addition to robot-assisted trainingcTBS + iTBS, in addition to robot-assisted training

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • with a diagnosis of a unilateral ischemic or hemorrhagic stroke;
  • with stroke onset more than 6 months;
  • from 18 to 75 years old;
  • with mild to moderate impairment of upper limb functions due to stroke, measured using the Hong Kong Version of the Functional Test for the Hemiplegic Upper Extremity (FTHUE-HK) from level 2 to level 7;
  • be able to understand verbal instruction and follow one-step commands;
  • be able to give informed consent to participate;

You may not qualify if:

  • any contraindications to rTMS/TBS, such as unstable medical condition, history of epileptic seizures, metal implants in vivo (eg, pacemaker, artificial cochlear, and implant brain stimulator), and a history of receiving craniotomy;
  • previous diagnosis of any neurological disease excluding stroke;
  • presence of any sign of cognitive problems (Abbreviated mental test Hong Kong version \< 6/10);
  • patients with extreme spasticity in any hemiplegic upper limb joint (Modified Ashworth score \> 2) or severe pain that hinder the upper limb motor training;
  • with other notable impairment of the upper limb affected by stroke, eg, recent fracture, severe osteoarthritis, congenital upper limb deformity
  • any sign of anxiety or depression, as assessed by the Hospital Anxiety and Depression Scale.
  • concurrent participation in an upper limb rehabilitation program or a medicine trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Hong Kong Polytechnic University, Department of Rehabilitation Sciences

Hong Kong, Hong Kong

Location

Related Publications (2)

  • Zhang JJ, Bai Z, Fong KNK. Priming Intermittent Theta Burst Stimulation for Hemiparetic Upper Limb After Stroke: A Randomized Controlled Trial. Stroke. 2022 Jul;53(7):2171-2181. doi: 10.1161/STROKEAHA.121.037870. Epub 2022 Mar 23.

  • Zhang JJ, Fong KNK. Effects of priming intermittent theta burst stimulation on upper limb motor recovery after stroke: study protocol for a proof-of-concept randomised controlled trial. BMJ Open. 2020 Mar 8;10(3):e035348. doi: 10.1136/bmjopen-2019-035348.

MeSH Terms

Conditions

Stroke

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

July 23, 2019

First Posted

July 26, 2019

Study Start

September 9, 2019

Primary Completion

June 1, 2021

Study Completion

August 1, 2021

Last Updated

August 30, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

The data will be shared for research purpose upon reasonable request.

Locations